Phase 3
N=246
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Dysfunctional Central Venous Access Catheters
Bottom Line
View on ClinicalTrials.gov: NCT00396318 ↗Enrolled (actual)
246
Serious AEs
2.4%
Results posted
Apr 2011
Primary outcome: Primary: Percentage of Patients Who Had Cumulative Restoration Rates of Central Venous Catheter (CVC) Function Following a Single Administration of Tenecteplase — 72.0 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- tenecteplase (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Genentech, Inc.
- Primary completion
- Jun 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Patients Who Had Cumulative Restoration Rates of Central Venous Catheter (CVC) Function Following a Single Administration of Tenecteplase |
72.0 | — |
| SECONDARY Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Single Administration of Tenecteplase |
53.3 | — |
| SECONDARY Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Single Administration of Tenecteplase |
53.3 | — |
| SECONDARY Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase |
81.3 | — |
| SECONDARY Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase |
81.3 | — |
| SECONDARY Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase |
81.3 | — |
| SECONDARY Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following Administration of One or Two Doses of Tenecteplase |
72.0; 81.3 | — |
| SECONDARY Percentage of Patients Who Had Cumulative Restoration Rates Restoration Rates of CVC Function at Any Time During the Study and Who Maintained Catheter Patency the Next Time the Catheter Was Assessed, up to 7 Days Following the Last Dose of Tenecteplase |
81.0 | — |
Summary
This was a Phase III, open-label, single-arm study that was conducted at 43 centers in the United States and Canada. 251 adult and pediatric patients with dysfunctional central venous catheters (CVCs) were enrolled in the study and treated with one or two doses of tenecteplase.
Eligibility Criteria
Inclusion Criteria
- Clinically stable, in the opinion of the investigator
- CVC occlusion
- Able to have fluids infused at the volume necessary to instill study drug into the CVC
Exclusion Criteria
- Able to have 3 mL of blood (patients weighing ≥ 10 kg) or 1 mL of blood (patients weighing < 10 kg) withdrawn from the selected CVC following patient repositioning
- Selected study CVC inserted < 2 days prior to treatment
- Selected study CVC implanted specifically for hemodialysis (HD) or internally coated with any therapeutic agent
- Use of a power injector on the selected study CVC during study drug treatment
- Evidence of mechanical, non-thrombotic occlusion of the selected study CVC (e.g., kink in the catheter or suture constricting the catheter)
- Previously treated in this study or any tenecteplase catheter clearance trial
- Use of any investigational drug or therapy within 28 days prior to treatment
- Use of a fibrinolytic agent (e.g., alteplase, tenecteplase, reteplase, or urokinase) within 24 hours prior to treatment
- Known to be pregnant or breastfeeding at screening
- Known bacteremia or known or suspected infection in the CVC catheter
- Known history of intracranial hemorrhage (within the previous 3 years), intracranial aneurysm, or arteriovenous malformation
- Use of heparin (unfractionated or low molecular weight) or any other anticoagulants within 24 hours prior to treatment, except heparin used for prophylaxis or intermittent or low-dose, continuous infusion of heparin to maintain catheter or vessel patency
- Subjects treated with warfarin only: international normalized ratio (INR) ≥ 3.0 within 7 days prior to Visit 1, or a target INR range that allows for an INR ≥ 3.0
- Initiation of or increase in dose of Plavix® (clopidogrel bisulfate) within 7 days prior to treatment
- At high risk for bleeding events or embolic complications (i.e., recent pulmonary embolus, deep vein thrombosis, endarterectomy, or clinically significant right-to-left shunt) in the opinion of the investigator, or with known condition for which bleeding constitutes a significant hazard
- Known hypersensitivity to tenecteplase or any component of the formulation
Data sourced from ClinicalTrials.gov (NCT00396318). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.